These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 11948140

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A, Kassis J, Kharait S, Kloeker S, Manos E, Jones DA, Wells A.
    Exp Cell Res; 2004 Sep 10; 299(1):91-100. PubMed ID: 15302576
    [Abstract] [Full Text] [Related]

  • 5. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
    Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG, Wells A.
    Clin Cancer Res; 1999 Aug 10; 5(8):2251-60. PubMed ID: 10473113
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells.
    Way TD, Lee JC, Kuo DH, Fan LL, Huang CH, Lin HY, Shieh PC, Kuo PT, Liao CF, Liu H, Kao JY.
    J Agric Food Chem; 2010 Mar 24; 58(6):3356-65. PubMed ID: 20166659
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular inhibition of phospholipase cgamma signaling abrogates DU-145 prostate tumor cell invasion.
    Turner T, Epps-Fung MV, Kassis J, Wells A.
    Clin Cancer Res; 1997 Dec 24; 3(12 Pt 1):2275-82. PubMed ID: 9815625
    [Abstract] [Full Text] [Related]

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 11. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G.
    Prostate; 2006 Feb 01; 66(2):200-10. PubMed ID: 16173040
    [Abstract] [Full Text] [Related]

  • 13. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice.
    Dondi D, Moretti RM, Montagnani Marelli M, Pratesi G, Polizzi D, Milani M, Motta M, Limonta P.
    Int J Cancer; 1998 May 18; 76(4):506-11. PubMed ID: 9590126
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M, Moretti RM, Mai S, Procacci P, Limonta P.
    Int J Oncol; 2007 Jan 18; 30(1):261-71. PubMed ID: 17143537
    [Abstract] [Full Text] [Related]

  • 18. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2002 Nov 18; 8(11):3438-44. PubMed ID: 12429632
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
    Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, van Meel JC.
    J Pharmacol Exp Ther; 2004 Nov 18; 311(2):502-9. PubMed ID: 15199094
    [Abstract] [Full Text] [Related]

  • 20. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY.
    J Pathol; 2005 Jun 18; 206(2):205-13. PubMed ID: 15818594
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.